Home » Novartis Buys Exclusive Rights to Anti-Smoking 'Vaccine'
Novartis Buys Exclusive Rights to Anti-Smoking 'Vaccine'
Novartis AG said Wednesday it will pay Cytos
Biotechnology AG up to 600 million Swiss francs (US$500 million; €366 million)
for the exclusive right to develop, produce and market an experimental drug it
hopes will help cure smokers of their habit.
International
Herald Tribune
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May